Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells.

PloS one - 1 Jan 2022

Harper Megan M, Lin Miranda, Cavnar Michael J, Pandalai Prakash K, Patel Reema A, Gao Mei, Kim Joseph

Abstract excerpt

Despite recent therapeutic advances, pancreatic ductal adenocarcinoma (PDAC) remains a devastating disease with limited therapeutic options. Immune checkpoint inhibitors (ICIs) have demonstrated promising results in many cancers, but thus far have yielded little clinical benefit in PDAC. Based on recent combined targeting of programmed cell death protein-1 (PD-1) and C-X-C chemokine receptor 4 (CXCR4) in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Pancreatic Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Phenotype

Share to Programmed Cell Death 1 Receptor

Share to Receptors, CXCR4

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 35797269
DOI: 10.1371/journal.pone.0270832
PMCID: PMC9262213

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells.PMID 35797269Read ↗

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implicationsSemantic proximity Read ↗

Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical TargetsSemantic proximity Read ↗

A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.Semantic proximity Read ↗

Identification of a novel immune checkpoint molecule V‐set immunoglobulin domain‐containing 4 that leads to impaired immunity infiltration in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

The importance of CXCR4 expression in tumor stroma as a potential biomarker in pancreatic cancerSemantic proximity Read ↗

Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer CellsSemantic proximity Read ↗

Exploiting inflammation for therapeutic gain in pancreatic cancer.Semantic proximity Read ↗

Inhibition of P21-activated kinases 1 and 4 synergistically suppress the growth of pancreatic cancer by stimulating anti-tumour immunitySemantic proximity Read ↗

Disabling PSGL-1 abrogates immune suppression and resistance to PD-1 blockade in pancreatic cancerSemantic proximity Read ↗

Modulation of the tumor microenvironment by the CXCR4 antagonist AMD3100 in pancreatic and colorectal adenocarcinomaSemantic proximity Read ↗

TRAIL/NF-κB/CX3CL1 Mediated Onco-Immuno Crosstalk Leading to TRAIL Resistance of Pancreatic Cancer Cell LinesSemantic proximity Read ↗

PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.